Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers

Leukemia Research

Volumn 35, Issue 3, 2011, Pages 394-404

  Dubovsky, Jason A ^a   Wang, Daniel ^a   Powers, John J ^a   Berchmans, Emmanuel ^a   Smith, Matthew A ^b   Wright, Kenneth L ^a   Sotomayor, Eduardo M ^a   Pinilla Ibarz, Javier A ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

5 Aza 2 deoxycytidine; Cancer germline; Costimulatory; Histone deacetylase inhibitor; Immunotherapy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; B7 ANTIGEN; CANCER TESTIS ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; DACINOSTAT; F ACTIN; GAMMA INTERFERON; GRANZYME B; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PERFORIN;

ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOKINE RELEASE; DEMETHYLATION; EPIGENETICS; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL SYNAPSE; LEUKEMIA CELL; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH1 CELL;

ACETYLATION; ANTIGENS, NEOPLASM; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DNA METHYLATION; DRUG SYNERGISM; EPIGENOMICS; HISTONES; HUMANS; HYDROXAMIC ACIDS; IMMUNOPHENOTYPING; L-LACTATE DEHYDROGENASE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; T-LYMPHOCYTES; TESTIS; TH1 CELLS; TUMOR CELLS, CULTURED;

EID: 79952102186     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.08.001     Document Type: Article

References (49)

1. Ramsay A.G., Johnson A.J., Lee A.M., et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008.
2. Krackhardt A.M., Witzens M., Harig S., et al. Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood 2002, 100(6):2123-2131.
3. Ouillette P., Erba H., Kujawski L., et al. Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. Cancer Res 2008, 68(4):1012-1021.
4. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96.
5. Kay N.E., Rai K.R., O'Brien S. Chronic lymphocytic leukemia: current and emerging treatment approaches. Clin Adv Hematol Oncol 2006, 4(11 Suppl. 22):1-10. [quiz 11-2].
6. Rassenti L.Z., Jain S., Keating M.J., et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008, 112(5):1923-1930.
7. Fulci V., Chiaretti S., Goldoni M., et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 2007, 109(11):4944-4951.
8. Binet J.L., Auquier A., Dighiero G., et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981, 48(1):198-206.
9. Rai K.R., Sawitsky A., Cronkite E.P., et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975, 46(2):219-234.
10. Tam C.S., O'Brien S., Wierda W., et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008, 112(4):975-980.
11. Wierda W.G., Kipps T.J. Gene therapy and active immune therapy of hematologic malignancies. Best Pract Res Clin Haematol 2007, 20(3):557-568.
12. Molica S. Immunomodulatory drugs in chronic lymphocytic leukemia: a new treatment paradigm. Leuk Lymphoma 2007, 48(5):866-869.
13. Chanan-Khan A., Porter C.W. Immunomodulating drugs for chronic lymphocytic leukaemia. Lancet Oncol 2006, 7(6):480-488.
14. Ferrajoli A., Lee B.N., Schlette E.J., et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008, 111(11):5291-5297.
15. Wu L., Adams M., Carter T., et al. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008, 14(14):4650-4657.
16. Mosmann T.R., Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. [Review]. Annu Rev Immunol 1989, 7:145-173.
17. Horna P., Sotomayor E.M. Cellular and molecular mechanisms of tumor-induced T-cell tolerance. Curr Cancer Drug Targets 2007, 7(1):41-53.
18. Mellstedt H., Choudhury A. T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the devil. Cancer Immunol Immunother 2006, 55(2):210-220.
19. Scrivener S., Goddard R.V., Kaminski E.R., et al. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2003, 44(3):383-389.
20. Rush L.J., Raval A., Funchain P., et al. Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res 2004, 64(7):2424-2433.
21. Chen S.S., Raval A., Johnson A.J., et al. Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2009, 106(32):13433-13438.
22. Khan A.N., Magner W.J., Tomasi T.B. An epigenetically altered tumor cell vaccine. Cancer Immunol Immunother 2004, 53(8):748-754.
23. Khan A.N., Magner W.J., Tomasi T.B. An epigenetic vaccine model active in the prevention and treatment of melanoma. J Transl Med 2007, 5(1):64.
24. Khan A.N., Tomasi T.B. Histone deacetylase regulation of immune gene expression in tumor cells. Immunol Res 2008, 40(2):164-178.
25. Khan A.N., Gregorie C.J., Tomasi T.B. Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother 2008, 57(5):647-654.
26. Borden E.C. Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: potential application to melanoma. Cytokine Growth Factor Rev 2007, 18(5-6):491-501.
27. Dubovsky J.A., McNeel D.G., Powers J.J., et al. Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clin Cancer Res 2009, 15(10):3406-3415.
28. Guo Z.S., Hong J.A., Irvine K.R., et al. De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res 2006, 66(2):1105-1113.
29. Villagra A., Cheng F., Wang H.W., et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol 2009, 10(1):92-100.
30. Sailhamer E.A., Li Y., Smith E.J., et al. Acetylation: a novel method for modulation of the immune response following trauma/hemorrhage and inflammatory second hit in animals and humans. Surgery 2008, 144(2):204-216.
31. Blum K.A., Liu Z., Lucas D.M., et al. Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation. Br J Haematol 2010, 150(2):189-195.
32. Stacchini A., Aragno M., Vallario A., et al. MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res 1999, 23(2):127-136.
33. Wendel-Hansen V., Sallstrom J., De Campos-Lima P.O., et al. Epstein-Barr virus (EBV) can immortalize B-CLL cells activated by cytokines. Leukemia 1994, 8(3):476-484.
34. Schoenborn J.R., Wilson C.B. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 2007, 96:41-101.
35. Shnyreva M., Weaver W.M., Blanchette M., et al. Evolutionarily conserved sequence elements that positively regulate IFN-gamma expression in T cells. Proc Natl Acad Sci USA 2004, 101(34):12622-12627.
36. Tomasi T.B., Magner W.J., Khan A.N. Epigenetic regulation of immune escape genes in cancer. Cancer Immunol Immunother 2006, 55(10):1159-1184.
37. Sjoberg J., Aguilar-Santelises M., Sjogren A.M., et al. Interleukin-10 mRNA expression in B-cell chronic lymphocytic leukaemia inversely correlates with progression of disease. Br J Haematol 1996, 92(2):393-400.
38. Quintana A., Schwindling C., Wenning A.S., et al. T cell activation requires mitochondrial translocation to the immunological synapse. Proc Natl Acad Sci USA 2007, 104(36):14418-14423.
39. Oakes S.A. Mitochondria control calcium entry at the immunological synapse. Proc Natl Acad Sci USA 2007, 104(39):15171-15172.
40. Vitale M., Zamai L., Neri L.M., et al. Natural killer function in flow cytometry: identification of human lymphoid subsets able to bind to the NK sensitive target K562. Cytometry 1991, 12(8):717-722.
41. Morgan M.M., Labno C.M., Van Seventer G.A., et al. Superantigen-induced T cell:B cell conjugation is mediated by LFA-1 and requires signaling through Lck, but not ZAP-70. J Immunol 2001, 167(10):5708-5718.
42. Plass C., Byrd J.C., Raval A., et al. Molecular profiling of chronic lymphocytic leukaemia: genetics meets epigenetics to identify predisposing genes. Br J Haematol 2007, 139(5):744-752.
43. Fink S.L., Cookson B.T. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun 2005, 73(4):1907-1916.
44. Rossmann E.D., Lewin N., Jeddi-Tehrani M., et al. Intracellular T cell cytokines in patients with B cell chronic lymphocytic leukaemia (B-CLL). Eur J Haematol 2002, 68(5):299-306.
45. Tangye S.G., Raison R.L. Human cytokines suppress apoptosis of leukaemic CD5+ B cells and preserve expression of bcl-2. Immunol Cell Biol 1997, 75(2):127-135.
46. Vatolin S., Abdullaev Z., Pack S.D., et al. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res 2005, 65(17):7751-7762.
47. Klenova E.M., Morse H.C., Ohlsson R., et al. The novel BORIS+CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. Semin Cancer Biol 2002, 12(5):399-414.
48. Loukinov D.I., Pugacheva E., Vatolin S., et al. BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc Natl Acad Sci USA 2002, 99(10):6806-6811.
49. Dubovsky J.A., McNeel D.G. Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor. Prostate 2007, 67(16):1781-1790.